Pharmacogenomics of high-density lipoprotein-cholesterol-raising therapies.
about
Precision medicine: from pharmacogenomics to pharmacoproteomicsPharmacogenomics, lipid disorders, and treatment options.HDL and atherosclerotic cardiovascular disease: genetic insights into complex biology.Genetic coding variants in the niacin receptor, hydroxyl-carboxylic acid receptor 2, and response to niacin therapy.
P2860
Pharmacogenomics of high-density lipoprotein-cholesterol-raising therapies.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Pharmacogenomics of high-density lipoprotein-cholesterol-raising therapies.
@en
Pharmacogenomics of high-density lipoprotein-cholesterol-raising therapies.
@nl
type
label
Pharmacogenomics of high-density lipoprotein-cholesterol-raising therapies.
@en
Pharmacogenomics of high-density lipoprotein-cholesterol-raising therapies.
@nl
prefLabel
Pharmacogenomics of high-density lipoprotein-cholesterol-raising therapies.
@en
Pharmacogenomics of high-density lipoprotein-cholesterol-raising therapies.
@nl
P2860
P50
P356
P1476
Pharmacogenomics of high-density lipoprotein-cholesterol-raising therapies
@en
P2093
Robert J Straka
Stella Aslibekyan
P2860
P304
P356
10.1586/ERC.12.134
P577
2013-03-01T00:00:00Z